Core Viewpoint - The European Union has implemented the International Procurement Instrument (IPI) measures, restricting Chinese companies and products from entering the EU public procurement market for medical devices, effective June 30, 2023 [2][3]. Summary by Categories Impact of IPI Measures - The IPI measures exclude Chinese companies from participating in EU public procurement projects exceeding €5 million, and require that products and components from China do not exceed 50% in winning bids for projects below this threshold [3][4]. - The IPI measures are expected to significantly impact Chinese medical device companies, as approximately 60% of the industry procurement amount is affected by the ban on projects over €5 million [6]. Specific Restrictions - The restrictions include monetary limits, percentage limits, scope limits, and time limits. The measures cover a wide range of medical devices, including masks, protective equipment, medical imaging devices, and surgical robots [4]. - The IPI measures will be effective for five years, with the possibility of a one-time extension for an additional five years [4]. Industry Reactions - Experts believe that the IPI measures will create substantial barriers for Chinese medical device companies seeking to enter the EU market, reflecting the EU's anxiety over the competitive impact of Chinese firms [5][6]. - Some companies, like Mindray Medical, assert that the impact of the IPI measures will be limited, as they do not currently have contracts exceeding €5 million in the EU [7]. Strategic Responses - Chinese medical device companies are expected to enhance compliance management and localize production to mitigate the impact of the IPI measures [9][10]. - Companies are exploring diversified strategies, such as "China innovation + overseas production + global delivery," to avoid the restrictions imposed by the EU [10]. Market Performance - Following the announcement of the IPI measures, stock prices of leading medical device companies like Mindray Medical and United Imaging did not decline, indicating a potential resilience in the market [8].